← Leaderboards
Lijun Rong
University Of Illinois At Chicago
$20,259,069
Attributed
$20,471,351
Total exposure
16
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,471,351 · 16
By mechanism
R01$6,818,875 · 3
R42$6,214,495 · 2
R41$4,694,583 · 8
U01$2,085,884 · 1
R21$424,564 · 1
R03$232,950 · 1
Top collaborators
- Christopher Broder2 shared
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Judy L. Bolton$10,491,560
Others in their field
Top investigators on “Animal Model”
- David Heimbrook · Leidos Biomedical Research, Inc.$464,525,875
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Joseph E Robertson · Oregon Health & Science University$126,125,279
- Peter Gordon Gillespie · Oregon Health And Science University$105,808,119
- David M Anderson · University Of Washington$102,920,737
- Polly Chang · Sri International$84,271,267
Research focus
Animal ModelVirusPropertyVirus DiseasesLeadSmall MoleculeStructureBaseExhibitsDrug KineticsSeriesIn VitroLibrariesScaffoldAnalogDoseMediatingGlycoproteinsViralVaccinesInhibitor/AntagonistDesignInfectionSafety
Grant awards (45)
Optimizing Ridaifen-B analogs as potential therapeutics for Ebola viruses$1,574,644
R01 · FY2025 · AI · contact PI
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics$999,234
R42 · FY2024 · AI · contact PI
Optimizing Ridaifen-B analogs as potential therapeutics for Ebola viruses$787,393
R01 · FY2024 · AI · contact PI
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics$999,369
R42 · FY2023 · AI · contact PI
Optimizing Ridaifen-B analogs as potential therapeutics for Ebola viruses$780,190
R01 · FY2023 · AI · contact PI
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics$999,369
R42 · FY2022 · AI · contact PI
Optimizing Ridaifen-B analogs as potential therapeutics for Ebola viruses$795,165
R01 · FY2022 · AI · contact PI
Furopyrimidines as novel inhibitors of henipaviruses$299,667
R41 · FY2022 · AI · contact PI
4-(Aminomethyl) benzamides as novel anti-Ebola agents$982,388
R42 · FY2021 · AI · contact PI
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics$300,000
R42 · FY2021 · AI · contact PI
Furopyrimidines as novel inhibitors of henipaviruses$299,595
R41 · FY2021 · AI · contact PI
4-(Aminomethyl) benzamides as novel anti-Ebola agents$961,660
R42 · FY2020 · AI · contact PI
Development of group 2 influenza A virus entry inhibitors$299,999
R41 · FY2020 · AI · contact PI
4-(Aminomethyl) benzamides as novel anti-Ebola agents$972,475
R42 · FY2019 · AI · contact PI
Development of group 2 influenza A virus entry inhibitors$299,999
R41 · FY2019 · AI · contact PI
A Recombinant Cedar Virus-based Henipavirus Replication Platform for High-throughput Inhibitor Screening$193,928
R21 · FY2019 · AI
A Recombinant Cedar Virus-based Henipavirus Replication Platform for High-throughput Inhibitor Screening$230,636
R21 · FY2018 · AI
4-(Aminomethyl) benzamides as novel anti-Ebola agents$363,598
R41 · FY2017 · AI · contact PI
4-Aminopiperidines as novel anti-influenza agents$153,183
R41 · FY2017 · AI · contact PI
4-(Aminomethyl) benzamides as novel anti-Ebola agents$363,601
R41 · FY2016 · AI · contact PI
GPCR antagonists as anti-Ebola virus entry inhibitors$297,665
R41 · FY2016 · AI · contact PI
Novel filovirus entry inhibitors based on a pseudo-symmetrical biphenyl core$288,106
R41 · FY2016 · AI · contact PI
4-Aminopiperidines as novel anti-influenza agents$242,913
R41 · FY2016 · AI · contact PI
New heterocyclic inhibitors of filoviruses$300,000
R41 · FY2015 · AI · contact PI
GPCR antagonists as anti-Ebola virus entry inhibitors$299,392
R41 · FY2015 · AI · contact PI
New small molecule inhibitors of arenaviruses$298,297
R41 · FY2015 · AI · contact PI
Novel filovirus entry inhibitors based on a pseudo-symmetrical biphenyl core$288,568
R41 · FY2015 · AI · contact PI
New heterocyclic inhibitors of filoviruses$300,000
R41 · FY2014 · AI · contact PI
New small molecule inhibitors of arenaviruses$300,000
R41 · FY2014 · AI · contact PI
Screening and development of anti-Ebola entry inhibitors$893,317
U01 · FY2010 · AI · contact PI
Screening and development of anti-Ebola entry inhibitors$1,192,567
U01 · FY2009 · AI · contact PI
Elucidating the Entry Mechanism of Ebola Viruses$322,069
R01 · FY2009 · AI · contact PI
Elucidating the Entry Mechanism of Ebola Viruses$322,069
R01 · FY2008 · AI · contact PI
Elucidating the Entry Mechanism of Ebola Viruses$328,308
R01 · FY2007 · AI · contact PI
Elucidatng the Entry Mechanism of Ebola Viruses$338,113
R01 · FY2006 · AI · contact PI
Elucidating the Entry Mechanism of Ebola Viruses$322,500
R01 · FY2005 · AI
ROLES OF A SIMPLE RECEPTOR IN RETROVIRAL INFECTION$260,495
R01 · FY2005 · CA
ROLES OF A SIMPLE RECEPTOR IN RETROVIRAL INFECTION$245,495
R01 · FY2004 · CA
ROLES OF A SIMPLE RECEPTOR IN RETROVIRAL INFECTION$245,495
R01 · FY2003 · CA
ROLES OF A SIMPLE RECEPTOR IN RETROVIRAL INFECTION$15,000
R01 · FY2003 · CA
ROLES OF A SIMPLE RECEPTOR IN RETROVIRAL INFECTION$245,495
R01 · FY2002 · CA
ANALYSIS OF HEPATITIS C VIRUS ENTRY$77,650
R03 · FY2002 · AI
ROLES OF A SIMPLE RECEPTOR IN RETROVIRAL INFECTION$236,444
R01 · FY2001 · CA
ANALYSIS OF HEPATITIS C VIRUS ENTRY$77,650
R03 · FY2001 · AI
ANALYSIS OF HEPATITIS C VIRUS ENTRY$77,650
R03 · FY2000 · AI